Trial Profile
A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Atacicept (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms ATAMS
- Sponsors EMD Serono
- 05 Oct 2021 This trial has been completed in Spain and France (End Date: 30 May 2011), according to European Clinical Trials Database record.
- 09 Jun 2012 Planned number of patients changed from 250 to 332 as reported by European Clinical Trials Database (Parent trial: EudraCT2007-003936-50).
- 09 Jun 2012 Official Title amended as reported by European Clinical Trials Database (Parent trial: EudraCT2007-003936-50).